NasdaqGS:BEAMBiotechs
Beam Therapeutics Accelerated Approval Bid Puts BEAM-302 At Center Stage
Beam Therapeutics reported new clinical data from its BEAM-302 Phase 1/2 trial in alpha-1 antitrypsin deficiency, showing encouraging safety and efficacy signals.
Based on FDA feedback, the company plans to pursue an accelerated approval pathway and start a pivotal cohort for BEAM-302.
Beam intends to share more detailed BEAM-302 data later in the year, positioning this program as a key focus in its gene editing pipeline.
For investors tracking NasdaqGS:BEAM, this update highlights BEAM-302...